ORMP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ORMP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-03-23), Oramed Pharmaceuticals's 6-1 Month Momentum % is -6.93%.
The industry rank for Oramed Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:
For the Biotechnology subindustry, Oramed Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Oramed Pharmaceuticals's 6-1 Month Momentum % falls into.
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum % | = | ( Price 1-month ago | / | Price 6-month ago | - 1 ) | * | 100 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oramed Pharmaceuticals (NAS:ORMP) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Thank you for viewing the detailed overview of Oramed Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Benjamin Shapiro | director | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Nadav Kidron | director, 10 percent owner | 142 W. 57TH ST., NEW YORK NY 10019 |
Yadin Rozov | director | 9 TERRACE CIRCLE, ARMONK NY 10504 |
Miriam Kidron | director | 2 ELZA STREET, JERUSALEM L3 93706 |
Michael Rabinowitz | officer: Chief Commercial Officer | 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036 |
Arie Mayer | director | MORAN 16, KFAR SABA L3 4428890 |
Netanel Derovan | officer: Chief Legal Officer | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
David Silberman | officer: Chief Financial Officer | 20 MAMILLA AVENUE, JERUSALEM L3 9414904 |
Kevin Rakin | director | 36 CHURCH LANE, WESTPORT CT 06880 |
Michael Rabinowitz | officer: Chief Commercial Officer | MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174 |
Leonard Sank | director | 3 BLAIR ROAD, CAPE TOWN T3 8005 |
Gao Xiaoming | director | 11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001 |
Avraham Gabay | officer: CFO, Treasurer and Secretary | 2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390 |
Mark Daniel Hasleton | officer: VP Business Development | 13, HIBAT ZION, RAANANA, RAANANA L3 4338111 |
Aviad Friedman | director | HADASSA 6, TEL AVIV L3 6451306 |
From GuruFocus
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By PRNewswire PRNewswire • 01-04-2023
By PRNewswire PRNewswire • 05-15-2023
By PRNewswire PRNewswire • 11-09-2022
By PRNewswire PRNewswire • 12-21-2022
By PRNewswire PRNewswire • 11-17-2022
By PRNewswire • 10-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.